MASLD fatty liver disease linked to heart and kidney issues

Research indicates that metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is linked to increased risks of cardiovascular disease, chronic kidney disease, and premature death. Affecting approximately 30% to 40% of adults globally, the condition is often symptomless and may only be detected through routine medical scans.

Obesity is a primary driver of the condition, with prevalence rates reaching approximately 75% among individuals with obesity. The disease can progress to a more advanced inflammatory form known as metabolic dysfunction-associated steatohepatitis (MASH). While obesity, type 2 diabetes, and abnormal cholesterol are major risk factors, genetics and body-fat distribution also play significant roles. Projections suggest MASLD could affect more than half of the global adult population by 2040 due to rising rates of obesity and diabetes.